These findings suggest that mutations in different KRAS codons may have different effects on the resistance of rectal cancer to CRT and that the rectal cancers carrying KRAS and TP53 mutations are less likely to respond to CRT compared with wild‐type tumors. Here, TP53 is linked to rectal cancer.